Roberta Rolla1, Andreana De Mauri2, Ambra Valsesia1, Matteo Vidali1, Doriana Chiarinotti3, Giorgio Bellomo1. 1. Clinical Chemistry Laboratory, Department of Health Sciences, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy. 2. Nephrology and Dialysis Unit, University Hospital 'Maggiore della Carità', Corso Mazzini, 18, 28100, Novara, Italy. andreanademauri@libero.it. 3. Nephrology and Dialysis Unit, University Hospital 'Maggiore della Carità', Corso Mazzini, 18, 28100, Novara, Italy.
Abstract
BACKGROUND: Cardiovascular disease is the leading cause of morbidity and mortality in hemodialysis patients; the increased risk of cardiovascular disease is due to accelerated atherosclerosis, inflammation and impaired lipoprotein metabolism. We aimed to evaluate lipoprotein-associated phospholipase A2 (Lp-PLA2) and some pro-inflammatory aspects of the lipoprotein profile in dialyzed patients in order to evaluate the relationship with the accelerated atherosclerosis and vascular accidents. METHODS: In 102 dialysis patients and 40 non-uremic controls, we investigated the lipoprotein plasma profile, high sensitivity C-reactive protein (CRP), ceruloplasmin and serum amyloid A protein (SAA), and followed patients for 1 year to analyze the risk of acute cardiovascular events. RESULTS: Total cholesterol, low-density lipoprotein and high-density lipoprotein plasma levels were significantly lower in uremic patients than controls, whereas CRP, SAA, ceruloplasmin, Lp-PLA2 and their ratio with apolipoprotein A1 were significantly higher. Patients with Lp-PLA2 levels >194 nmol/min/ml had more acute cardiovascular events than patients with lower values. CONCLUSION: Our results show that in dialysis subjects: (1) low-density lipoproteins show a more atherogenic phenotype than in the general population; (2) high-density lipoproteins are less anti-inflammatory; (3) Lp-PLA2 could potentially be used to evaluate cardiovascular risk.
BACKGROUND:Cardiovascular disease is the leading cause of morbidity and mortality in hemodialysis patients; the increased risk of cardiovascular disease is due to accelerated atherosclerosis, inflammation and impaired lipoprotein metabolism. We aimed to evaluate lipoprotein-associated phospholipase A2 (Lp-PLA2) and some pro-inflammatory aspects of the lipoprotein profile in dialyzed patients in order to evaluate the relationship with the accelerated atherosclerosis and vascular accidents. METHODS: In 102 dialysis patients and 40 non-uremic controls, we investigated the lipoprotein plasma profile, high sensitivity C-reactive protein (CRP), ceruloplasmin and serum amyloid A protein (SAA), and followed patients for 1 year to analyze the risk of acute cardiovascular events. RESULTS: Total cholesterol, low-density lipoprotein and high-density lipoprotein plasma levels were significantly lower in uremicpatients than controls, whereas CRP, SAA, ceruloplasmin, Lp-PLA2 and their ratio with apolipoprotein A1 were significantly higher. Patients with Lp-PLA2 levels >194 nmol/min/ml had more acute cardiovascular events than patients with lower values. CONCLUSION: Our results show that in dialysis subjects: (1) low-density lipoproteins show a more atherogenic phenotype than in the general population; (2) high-density lipoproteins are less anti-inflammatory; (3) Lp-PLA2 could potentially be used to evaluate cardiovascular risk.
Authors: Nosratola D Vaziri; Yongli Bai; Jun Yuan; Hannah L Said; Whitney Sigala; Zhemin Ni Journal: Am J Nephrol Date: 2010-07-16 Impact factor: 3.754